Evidence map›Paper›PMID 33597098›Full record

ArticleClinical lymphoma, myeloma & leukemia2021

Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome.

Kiyomi Morita, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Joseph D Khoury, Shimin Hu, Guillermo Garcia-Manero, William Wierda, Ghayas Issa, Naval Daver and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Current status and novel strategy of CML.International journal of hematology · 2021
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Kiyomi MoritaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Shimin HuDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
William WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ghayas IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Kelly A SoltysiakDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sherry PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Carlos Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jorge CortesGeorgia Cancer Center, Augusta, GA.
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: ksasaki1@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USNational Cancer Center of Georgia · GE

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632
6 · The paper itself

Abstract

backgroundAcquisition of additional cytogenetic abnormalities (ACAs) in addition to Philadelphia chromosome is frequently observed in patients with chronic myeloid leukemia (CML) in advanced phase. The presence of core binding factor (CBF) translocations determines the diagnosis of acute myeloid leukemia regardless of blast percentage, and CBF rearrangements are rarely identified as ACAs. PATIENTS AND

methodsA retrospective chart review of patients with CML who had CBF rearrangement, t(8;21) or inv(16), in Philadelphia chromosome-positive clones was conducted. Additional cases of CML with CBF rearrangements were identified through literature review.

resultsBetween August 1997 and December 2014, we identified 11 patients who had Philadelphia chromosome and CBF rearrangement in the same clones: 1 (9%) with t(8;21) and 10 (91%) with inv(16). Nine (82%) patients were in blast phase, and 2 (18%) in second chronic phase. Four (36%) patients received tyrosine kinase inhibitor monotherapy, 2 (18%) received tyrosine kinase inhibitor and chemotherapy, and 5 (45%) received chemotherapy only. Three (27%) patients achieved complete remission with incomplete count recovery, and 4 (36%) had no response after the initial therapy. Three (27%) patients underwent allogeneic stem cell transplantation. The median event-free survival and overall survival for the 11 patients were 2 months and 6 months, respectively. Literature review identified 14 patients with CML with CBF rearrangement with a median overall survival of 14 months.

conclusionAcquisition of CBF rearrangement in addition to Philadelphia chromosome is a rare phenomenon associated with poor prognosis. CBF rearrangements as ACAs in patients with CML can be considered high-risk features.

Indexed as

AdultCore Binding FactorsFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPhiladelphia ChromosomeRetrospective StudiesTreatment OutcomeCore Binding FactorsAdditional cytogenetic abnormalitiesBlast phaseChronic myeloid leukemiaCore binding factorTyrosine kinase inhibitor

Identifiers

PMID33597098
PMCPMC11513896
OpenAlexW3119094339

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.